TherapeuticsMD (TXMD) Showing Signs Of Perilous Reversal Today

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified TherapeuticsMD ( TXMD) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified TherapeuticsMD as such a stock due to the following factors:

  • TXMD has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $16.3 million.
  • TXMD has traded 456,804 shares today.
  • TXMD is down 3% today.
  • TXMD was up 5.2% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in TXMD with the Ticky from Trade-Ideas. See the FREE profile for TXMD NOW at Trade-Ideas

More details on TXMD:

TherapeuticsMD, Inc., a U.S. women's healthcare product company, manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter, vitamins, and cosmetics. Currently there are 4 analysts that rate TherapeuticsMD a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for TherapeuticsMD has been 1.1 million shares per day over the past 30 days. TherapeuticsMD has a market cap of $870.1 million and is part of the health care sector and drugs industry. The stock has a beta of -0.05 and a short float of 10.4% with 3.34 days to cover. Shares are up 21.1% year-to-date as of the close of trading on Monday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates TherapeuticsMD as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and weak operating cash flow.

Highlights from the ratings report include:
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 46.3% when compared to the same quarter one year ago, falling from -$5.73 million to -$8.38 million.
  • Net operating cash flow has decreased to -$4.88 million or 12.37% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
  • THERAPEUTICSMD INC reported flat earnings per share in the most recent quarter. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, THERAPEUTICSMD INC continued to lose money by earning -$0.22 versus -$0.40 in the prior year. For the next year, the market is expecting a contraction of 22.7% in earnings (-$0.27 versus -$0.22).
  • Compared to other companies in the Pharmaceuticals industry and the overall market, THERAPEUTICSMD INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The gross profit margin for THERAPEUTICSMD INC is currently very high, coming in at 83.65%. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of -292.66% is in-line with the industry average.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Stocks Rise as Bond Yields Inch Closer to 3% Threshold

Stocks Rise as Bond Yields Inch Closer to 3% Threshold

Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations

Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations

Trump to Blame for Oil's Recent Surge, Not OPEC

Trump to Blame for Oil's Recent Surge, Not OPEC

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

U.S. Earnings On Pace for Best Season in Two Decades but Tech Giants Await

U.S. Earnings On Pace for Best Season in Two Decades but Tech Giants Await